Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve

NCT02147301 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02147301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02147301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve
Lead sponsor
University of California, San Francisco
Phase
Not applicable
Overall status
Terminated
Start date
December 17, 2014
Completion date
April 5, 2017
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoembolization, hepatocellular carcinoma